

Novel Nanotherapeutic Approaches for the Treatment of Emerging Multidrug Resistance

Limayem A^{1*}, Mohapatra SS² and Haller E³

¹Department of Cell Biology, Microbiology and Molecular Biology, University of South Florida, USA

²Division of Translational Medicine, Center for Education in Nanobioengineering (CERN), University of South Florida, USA

³Department of Integrative Biology, University of South Florida, USA

***Corresponding author:** Alya Limayem, Department of Cell Biology, Microbiology and Molecular Biology, University of South Florida, 4202 East Fowler Avenue, Tampa, FL 33620, USA, Tel: (813) 974-7404; E-mail: alimayem@usf.edu

Mini Review

Volume 1 Issue 2

Received Date: September 23, 2016

Published Date: October 18, 2016

Abstract

Realizing the high ability of multi-drug resistant fecal bacteria (MRFs) in developing resistance to every renewed conventional drug, alternative antimicrobials including natural nanocomponents have been explored. Synergism of the naturally occurring chitosan combined with Zinc Oxide (CZNPs) have been studied in our laboratories and has recently revealed an extraordinary antimicrobial potential against a broad spectrum of nosocomial MRFs. This article provides a condensed introduction on the most current knowledge of CZNPs properties including activities and selective toxicity. Potential effects of CZNPs on MRF strains in *vitro* and in *vivo* are also addressed.

Keywords: Chitosan; Zinc oxide; CZNPs synergism; MRFs (multidrug-resistant fecal bacteria); Nanotherapy

Introduction

The nosocomial infections from MRFs are attaining serious threat levels as they reach livestock and clinical settings [1-3]. Of parallel evolution, some MRF strains including gram-positive *Enterococcus faecium* and gram-negative *Escherichia coli* are the leading cause of bloodstream infection primarily in the immune compromised population [2]. They can be fatal if the appropriate choice of antibiotic is not prescribed at an early stage of the infection. In the USA, infections from the nosocomial MRFs together accounted for more than 120000 hospitalizations [4-7]. Therefore, exploring an alternative antimicrobial over the conventional antibiotic is becoming essential to mitigate the emerging multidrug

resistance and the fast approaching urgent level of threat. Natural nanocomponents that are safe and nontoxic to humans including chitosan and zinc oxide (ZnO) are holding promise not only for the treatment of MRF-induced disease [8] but would have impact in several other areas such as food industry, pharmaceuticals and agricultural applications [8]. The bioactive deacetylated, polysaccharide chitosan has been widely explored for its promising nano-scaled size and broad spectrum antimicrobial properties, combining several physicochemical and biological activities [9]. Its uniqueness arises from its high density of amino groups, revealing high biodegradability, biocompatibility and

functionality within a living host cell and a wide range of biomaterials [10]. This non-toxic chitin derivative is commercially extracted from crustacean shells and can be found in the cell walls of fungi in humans and animals, thus explaining the unresponsiveness of the immune system to it in the host cell. The FDA certified that chitosan not only contains transcellular properties to cross cellular membranes, but it also contains mucoadhesive and bioadhesive properties that contribute to its absorption-improving effects [11]. The cationic biopolymer was demonstrated effective against a wide range of microorganisms namely *E. coli*, *Salmonella Choleraesuis*, *S. Typhimurium*, and *Staphylococcus aureus* [12]. It is also suppressive to bacterial biofilms through its trans cellular and pervasive properties and could serve as a delivery system in the form of DNA-chitosan complex or antibiotic-chitosan synergism [13], adding more specificity and potency to the delivery system. Additionally, its $-NH_2$ polar group in the surface, owing the positive charge to the polysaccharide complex, enables chitosan interactions with metal oxides and minerals such as ZnO nanocomponent [11].

ZnO salt is recognized as safe (GRAS) by the US Food and Drug Administration (USDA) and has been widely used as antimicrobial nano-agent in food packaging materials [14,15]. It possesses a broad spectrum property with regard to its antimicrobial activity against a wide range of microorganisms including *Listeria monocytogenes*, *S. Enteritidis* and *Escherichia coli* O 157: H 7 [16]. ZnO has been primarily selected by industrials for its electrical, optical and photochemical properties allowing its applications in several biological and chemical areas [9]. Additionally, its nano-sized scale and surface-to-volume ratio surface reactivity increasing its anti-bacterial activity primarily against gram positive bacteria [15,17]. Being a photo oxidizing molecule, the nanoparticle of ZnO can generate reactive oxygen species (ROS) inside the host cell that would substantially impact the microbial cell wall causing loss of the proton motive force and uptake of toxic dissolved ions [18].

A side from its antimicrobial properties, the compound is covalent and shows some ionic properties that enable it to obtain semiconducting, electric conductivity, high optical absorption in the UVA and UVB regions and photocatalytic properties [19]. It thus enables ZnO to be more resistant to heat, temperature in addition to its high selectivity and long durability. The high UVA (315-400 nm) and UVB (280-315 nm) absorption that proves beneficial for antibacterial activity is characterized in ZnO

by a “wide band gap (3.3 eV) in the near-UV spectrum, a high excitonic binding energy (60 meV) at room temperature, and a natural n-type electrical conductivity”, properties that gives ZnO the opportunity to be used in various fields from cosmetics to an antimicrobial applicant [19,20]. While there are rare research studies that have reported some antiseptic and physico-chemical properties of chitosan combined with ZnO in cotton fabric in addition to UV protection [21,22], little is known about their nano micellar synergism efficacy against antibiotic resistant strains at a low molecular level. Potential effects of chitosan nanoparticle (10 kDA) combined to ZnO (CZNPs) are addressed in the next section.

Potential Effects of CZNPS *in Vitro*

A synergistic combination of both antimicrobial agents reveals the potential of the CZNPs on MRFs, demonstrating promising nano remedy results against gram-negative and gram-positive bacteria [8,23]. The combination of chitosan to ZnO nanoparticles (CZNPS) through a lipid micellar complex proved an extraordinary *in vitro* synergism potential against a broad continuum of gram-positive and gram-negative bacteria [8], where its effectiveness and mechanistic effects on MRFs microorganisms is shown in (Figure 1 and 2).




Figure 1: Mechanistic effect of CZNPs on gram-negative MRFs (*E. coli* 2471 BAA).




Figure 2: Mechanistic effect of CZNPs on gram-positive MRFs (*E. faecium* 1449).

Selective Toxicity of CZNPs

Recent studies revealed chitosan serves as an efficient drug-delivery system due to its poly cationic nature and ability to easily bind to metal oxides [24], such as zinc oxide. While chitosan concentration and molecular weight are estimated to measure the effects and magnitude of its toxicity, the size of the nanoparticle is of higher importance on conveying toxicity to chitosan [25,26]. Hu et al., 2011 performed toxicity tests at different concentrations and particle sizes against zebrafish, a cost-effect eukaryotic model. Results revealed that lower concentrations (5 $\mu\text{g}/\text{mL}$) and large particle size (340 nm) had significantly less toxic effects than larger concentrations (>20 $\mu\text{g}/\text{mL}$) and smaller particles (200 nm) [26]. Particle size was determined to be the major contributor for chitosan's toxicity, where as concentration plays a lesser role, according to Sarah et. al., 2015 [25]. Zinc oxide nanoparticles are known for their genotoxicity that can induce DNA damage and impair mitochondrial function in J774 macrophage cell lines [27] when administered at relatively-high concentrations. However, both chitosan and zinc oxides are considered to be efficient antimicrobial agents for their expression of selective toxicity that is attributed to their molecular charges and structure [21]; Regardless of particle size, chitosan nanoparticles are nontoxic at low concentrations (10-100 $\mu\text{g}/\text{mL}$) and can be nontoxic against eukaryotic cells at higher concentrations [25] while simultaneously

showing successful antimicrobial properties against gram-negative bacteria at concentrations of 1.875 mg/mL [8]. Zinc oxide nanoparticles proved to be selective in prokaryotic and eukaryotic systems, in Reddy et. al., 2007, ~13nm ZnO nanoparticles eliminated gram-negative *E. coli* at concentrations less than 3.4 mM and prevented growth of *S. Aureus* at concentrations less than 1 mM while showing no effect on human T cells [28]. Selective toxicity can be achieved as two separate agents depending on the concentration, particle size, and prokaryotic organism targeted [8,zebrafish]. The development of a nanomicelle provides a synergistic effect of both agents that could increase antimicrobial activity at a lower dosage of both particles.

Conclusions-Future prospects

CZNPs in form of lipid cross-linked nanomicelle complex (Figure 3) proved to be successfully effective against a broad continuum of multidrug resistant bacteria, MRFs *in vitro* and are currently tested on biofilms for its promising antimicrobial activity *in situ* [23]. Currently, the cross-linked nanomicellar CZNPs is being assessed against a microbial biofilm formed on "3D Fibrous Scaffold", which mimics the *in vivo* conditions [3,29]. These 3D forming biofilms (Figure 4) will not only model a bacterial *in vivo* environment but simulate MRF consortiums commonly formed in indwelling catheter devices in hospital settings [2]. Future prospects will also explore the effectiveness of a targeted multifunctional CZNPs that is sufficiently selective to inhibit MRFs *in vivo* without compromising the beneficial microbiota.




Figure 3: A schematic of CZNPs showing of core-shell structure with chitosan and ZnO-nanoparticles.




Figure 4: DAPI-fluorescent stain of *Enterococcus faecium* biofilm formed in 3D scaffold.

References

1. Austin DJ, Bonten MJ, Weinstein RA, Slaughter S, Anderson RM (1999) Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. *Proc Natl Acad Sci* 96(12): 6908-6913.
2. Arias CA, Murray BE (2012) The rise of the Enterococcus: beyond vancomycin resistance. *Nat Rev Microbiol* 10(4): 266-278.
3. Limayem A (2015) Tracking *Enterococcus faecium* antibiotic resistance, dissemination, and risk assessment modeling. *Agriculture Food and Analytical Bacteriology* 5(3).
4. Centers for Disease Control and Prevention (CDC) (2013) Antibiotic Resistance Threats in the United States
5. Lebreton F, van Schaik W, Manson McGuire A, Godfrey P, Griggs A, et al. (2013) Emergence of Epidemic Multidrug-Resistant *Enterococcus faecium* from Animal and Commensal Strains. *mBio* 4(4).
6. Eisenstein BI, Jones GW (1988) The spectrum of infections and pathogenic mechanisms of *Escherichia coli*. *Adv Intern Med* 33: 231-252.
7. Orskov I, Orskov F (1985) *Escherichia coli* in extra-intestinal infections. *J Hyg Lond* 95(3): 551-575.
8. Limayem A, Gonzalez F, Micciche A, Haller E, Nayak B, et al. (2016) Molecular identification and nanoremediation of microbial contaminants in algal systems using untreated wastewater. *J Environ Sci Health B*: 1-5.
9. Zhang H, Oh M, Allen C, Kumacheva E (2004) Monodisperse chitosan nanoparticles for mucosal drug delivery. *Biomacromolecules* 5(6): 2461-2468.
10. Zheng L, Zhu J (2003) Study on Antimicrobial Activity of Chitosan with Different Molecular Weights. *Carbohydrate Polymers* 54(4): 527-530.
11. Zhang H, Huang X, Sun Y, Xing J, Yamamoto A, et al. (2015) Absorption-improving effects of chitosan oligomers based on their mucoadhesive properties: A comparative study on the oral and pulmonary delivery of calcitonin. *Drug Deliv* 1-9.
12. Kubota N, Eguchi Y (1997) Facile preparation of water-soluble N-acetylated chitosan and molecular weight dependence of its water-solubility. *Polymer Journal* 29: 123-127.
13. Raafat D, von Barga K, Haas A, Sahl HG (2008) Insights into the Mode of Action of Chitosan as an Antibacterial Compound. *Appl Environ Microbiol* 74(12): 3764-3773.
14. Food and Drug Administration (1997).
15. Premanathan M, Karthikeyan K, Jeyasubramanian K, Manivannan G (2011) Selective toxicity of ZnO nanoparticles toward Gram-positive bacteria and cancer cells by apoptosis through lipid peroxidation. *Nanomedicine* 7(2): 184-192.
16. Jin T, Sun D, Su JY, Zhang H, Sue HJ (2009) Antimicrobial efficacy of zinc oxide quantum dots against *Listeria monocytogenes*, *Salmonella* Enteritidis, and *Escherichia coli* O157:H7. *J Food Sci* 74(1): 46-52.
17. Sahoo SK, Parveen S, Panda JJ (2007) The present and future of nanotechnology in human health care. *Nanomedicine* 3(1): 20-31.
18. Sawai J (2003) Quantitative evaluation of antibacterial activities of metallic oxide powders

- (ZnO, MgO and CaO) by conductimetric assay. *J Microbiol Methods* 54(2): 177-182.
19. Sirelkhatim A (2015) Review on Zinc Oxide Nanoparticles: Antibacterial Activity and Toxicity Mechanism 7(3): 219-242.
 20. Wang ZL (2004) Zinc oxide nanostructures: growth, properties and applications. *J Phys Condens Matter* 16(25): 829-858.
 21. AbdElhady MM, (2012) Preparation and characterization of chitosan/zinc oxide nanoparticles for imparting antimicrobial and UV protection to cotton fabric. *International journal of carbohydrate chemistry*: 6.
 22. Perelshtein I, Ruderman E, Perkas N, Tzanov T, Beddow J, et al. (2013) Chitosan and chitosan-ZnO-based complex nanoparticles: formation, characterization, and antibacterial activity. *J Mater Chem B* 1(14): 1968-1976.
 23. Limayem A, Micciche A, Haller E, Zhang C, Mohapatra S (2015) Nanotherapeutics for the mutating multi-drug resistant fecal bacteria. *J NanotecNanosci* 1(2): 1-13.
 24. Chopra H, Ruhi G (2016) Eco friendly chitosan: An efficient material for water purification. *The Pharma Innovation Journal* 5(1): 92-95.
 25. Sarah S, Zaki O, Ibrahim M, Katas H (2015) Particle Size Affects Concentration-Dependent Cytotoxicity of Chitosan Nanoparticles towards Mouse Hematopoietic Stem Cells. *Journal of Nanotechnology* 2015(2015): 5.
 26. Hu Y, Qi W, Han F, Gao JQ (2011) Toxicity evaluation of biodegradable chitosan nanoparticles using a zebrafish embryo model. *Int J Nanomedicine* 6: 3351-3359.
 27. Aude Garcia C, Dalzon B, Ravanat JL, Collin Faure V, Diemer H, et al. (2016) A combined proteomic and targeted analysis unravels new toxic mechanisms for zinc oxide nanoparticles in macrophages. *J Proteomics* 134: 174-185.
 28. Reddy K, Feris K, Bell J, Wingett D, Hanley C, et al. (2007) Selective toxicity of zinc oxide nanoparticles to prokaryotic and eukaryotic systems. *Appl Phys Lett* 90.
 29. Girard YK, Chunyan W, Ravi S, Howell M, Mallela J, et al. (2013) A 3D Fibrous Scaffold Inducing Tumoroids: A Platform for Anticancer Drug Development. *PLoS ONE* 8(10).